Gynecologic Cancer

Show only recruiting trials?

Roche.png

OZM-058

A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients with Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer (The NEO trial)

Status

Recruiting

JCP

JCP059

NCT

NCT02489006

Roche.png

DUO-E | D9311C00001

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E)

Status

Opening Soon

JCP

JCP078

NCT

NCT04269200

Roche.png

CX.5 | SHAPE

A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early Stage Cervical Cancer (SHAPE)

Status

Closed to Accrual

JCP

CX.5

NCT

NCT01658930

Roche.png

DUO-O | D081RC00001

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (DUO-O)

Status

Closed to Accrual

JCP

JCP092

NCT

NCT03737643

Roche.png

ORZORA

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer (ORZORA)

Status

Closed to Accrual

JCP

JCP023

NCT

NCT02476968

Roche.png

OVC.1

A Phase III Study Comparing Single-agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in Women with Recurrent Platinum-sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status

Closed to Accrual

JCP

OVC.1

NCT

NCT02446600

Roche.png

OVC.2

A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)

Status

Closed to Accrual

JCP

OVC.2

NCT

NCT02502266

Roche.png

PRIMA

A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Status

Closed to Accrual

JCP

JCP012

NCT

NCT02655016

Roche.png

R2810-ONC-1676

An Open-Label, Randomized, Phase 3 Clinical Trial Of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma

Status

Closed to Accrual

JCP

JCP030

NCT

NCT03257267

Roche.png

WO42017 | Skyscraper 04

A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer (SKYSCRAPER-04)

Status

Closed to Accrual

JCP

JCP083

NCT

NCT04300647

Filter Clinical Trials by:

arrow&v
arrow&v
arrow&v
arrow&v

Biomarkers:

No trials match your search criteria